Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, a mouse model of scarring alopecia demonstrated significantly reduced CD200R expression in affected skin, which may contribute to immune attacks on hair follicles.

This review suggests that excessive facial photoprotection could play a role in frontal fibrosing alopecia through a disturbance in immunological balance via the aryl hydrocarbon receptor-kynurenine pathway.

This article discusses the anatomical and biological aspects of hair follicle stem cells in the bulge region but reports no new research findings.

This study suggests that miR-486 may protect against alopecia areata by maintaining hair follicle immune privilege and modulating expression of immune-related genes.

This study found that bulge cells marked by CD200+ in human hair follicles show high colony-forming efficiency, suggesting successful enrichment of keratinocyte stem cells.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

This review examines the immunological aspects of alopecia areata, focusing on genetic, neuroimmunological, and immune privilege factors, but does not report new clinical findings.

This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.

This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.

This review discusses the interplay between hormonal and immune systems in hair follicles and reports no new results, highlighting the need for further research on their role in skin biology and alopecia areata.

This review discusses the role of perifollicular macrophages in hair growth and suggests targeting them could be relevant for managing hair growth disorders, but reports no new results.

This study indicates that innate lymphoid cells-type 1 may provoke alopecia areata by disrupting hair follicle immune privilege and inducing characteristic lesions, challenging the view that alopecia areata is purely an autoantigen-dependent, T cell-driven condition.

This review discusses current and emerging therapies for alopecia areata, highlights the challenges in managing this chronic disease, and emphasizes the importance of addressing its psychosocial impacts; it reports no new clinical results.

This review discusses the histological features and diagnostic challenges of alopecia areata and emphasizes the need for genetic research to develop future therapeutics; it reports no new clinical findings.

This paper proposes that the induction of HF-specific neo-antigens by peripheral CD8+ T cells may maintain self-tolerance but could also lead to immunopathology in conditions like alopecia areata.

This study found that alopecia areata is linked to genetic factors, specifically HLA haplotypes on chromosome 6, and involves immune privilege collapse at hair follicles which is mediated by the JAK-STAT pathway and pro-inflammatory cytokines like IFN-γ.

Sorafenib may cause hair loss in a way similar to alopecia areata.

This review discusses the association between oxidative stress and alopecia areata while proposing antioxidants as a potential supplementary therapy, but it reports no new clinical results.

This review discusses the biology and pathology of hair growth, exploring novel therapies like sublingual minoxidil and Janus kinase inhibitors, but reports no new clinical data.

This study found that Aire‒/‒ mice spontaneously developed persistent AA-like lesions, highlighting a potential role for AIRE in hair follicle biology and pathogenesis of alopecia areata.

This review discusses recent advances in the treatment of alopecia areata, highlighting new potential therapies like JAK inhibitors and PRP, and reports no new clinical results.

This article reviews treatments for alopecia areata, including corticosteroids and other immunomodulators, and reports no new experimental findings.

This study suggests that human dermal Vδ1+ γδ T-cells may contribute to alopecia areata pathogenesis by targeting stressed scalp hair follicles and inducing immune privilege collapse.

This study concluded that advancements in understanding the immunological mechanisms of alopecia areata have led to promising therapies, particularly JAK inhibitors and novel drug delivery systems, but further research is needed for clinical application.

In this review, researchers conclude that immune imbalance between regulatory and cytotoxic T cells, along with activation of IFN-γ–MHC and IL-15–NK pathways, disrupts hair follicle immune privilege, suggesting pivotal mechanisms in alopecia areata development and potential targets for immunotherapeutic interventions.

This article discusses baricitinib, a JAK1 and JAK2 inhibitor, as an approved and promising treatment for alopecia areata but reports no new clinical results.

This source highlights that the incidence of alopecia areata is increasing among children, and while corticosteroids and Janus kinase inhibitors show potential effectiveness and safety, they remain unapproved by the FDA for pediatric use.

This pilot study suggests that lovastatin may counteract stress-induced MICA expression in hair follicles and enhance MICA shedding, potentially offering a complementary approach for alopecia areata treatment.

This study provides evidence that innate lymphoid cells-type 1 can induce alopecia areata in human hair follicles, challenging the view that it is solely a CD8+ T cell-driven autoimmune disease.

This study found that the proprietary aptamer TAGX-0003 significantly inhibited IFNγ-induced effects in pre-clinical human models of alopecia areata, promoting hair regrowth and potentially preventing disease relapse.